几乎半数(16种)是“优先审评,”下批准其中FDA有6个月目标完成安全性和有效性审评。

Almost half (16) were approved under “priority review,” in which the FDA has a six month goal to complete its review for safety and effectiveness;

youdao

几乎半数(16种)是“优先审评,”下批准其中FDA有6个月目标完成安全性和有效性审评。

Almost half (16) were approved under “priority review,” in which the FDA has a six month goal to complete its review for safety and effectiveness;

youdao